EP Patent

EP0331232A2 — 5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols

Assigned to Janssen Pharmaceutica NV · Expires 1989-09-06 · 37y expired

What this patent protects

5-Lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols having the formula wherein R 1 and R 2 each independently are hydrogen, C 1-6 alkyl or halo; R 3 and R 4 each independently are hydrogen, halo, amino, nitro or trifluoromethyl; Y is a heterocyclic radical of for…

USPTO Abstract

5-Lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols having the formula wherein R 1 and R 2 each independently are hydrogen, C 1-6 alkyl or halo; R 3 and R 4 each independently are hydrogen, halo, amino, nitro or trifluoromethyl; Y is a heterocyclic radical of formula for use as a medicine. Compositions containing these compounds as active ingredient. Novel 4-(4-phenyhl-1-piperazinyl)phenols and methods for preparing these and the aforementioned compositions.

Drugs covered by this patent

Patent Metadata

Patent number
EP0331232A2
Jurisdiction
EP
Classification
—
Expires
1989-09-06
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Pharmaceutica NV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.